1. Amongst patients with advanced renal-cell carcinoma and an intermediate or poor prognosis, nivolumab plus ipilimumab was superior to sunitinib alone in improving overall survival. 2. Though not statistically compared, there was a lower incidence of grade three or four adverse events with nivolumab plus ipilimumab, although more patients in the combination therapy arm stopped 
An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.
The employment of radical nephrectomy, vs partial nephrectomy, was found to cause a 2-fold greater decline in eGFR decline and greatly increased mortality.
Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.
Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.
Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
Practical Management of Adverse Events Associated With Cabozantinib Treatment in Patients With Renal-cell CarcinomaNovember 24, 2017
[OncoTargets and Therapy] This research reviews the management of the more common adverse events associated with cabozantinib treatment for patients with patients with advanced clear-cell renal-cell carcinoma.
Although use of medical co-management and rehabilitation services increasing for older patients with kidney cancer, consultation remains sparse for those undergoing surgery.
Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).
Complete surgical metastasectomy correlated with increased survival in patients with metastatic renal cell carcinoma (mRCC) compared with incomplete surgical metastasectomy.
Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.
Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.
Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.
Alternating treatment with pazopanib and everolimus failed to prolong progression-free survival compared with continuous pazopanib.
Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient SelectionOctober 13, 2016
[OncoTargets and Therapy] This research We reviews the development of cabozantinib in advanced renal cell carcinoma and its role in the treatment landscape.
A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.
Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.
A potential cancer therapy with a unique strategy to block the mTOR molecule has been designed. This new mTOR-inhibiting compound reduced the size of tumors resistant to earlier-generation mTOR inhibitors.
Several genetic differences uncovered in an analysis of data from The Cancer Genome Atlas (TCGA) are biologically plausible contributing factors for the worse survival of African American patients with clear cell renal carcinoma, even in the era of targeted therapy.
Adjuvant treatment with sorafenib or sunitinib demonstrated no survival benefit in patients with resected local renal cell carcinoma at high risk for disease recurrence.
Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor VaccineMarch 04, 2016
In this study, researchers sought to characterize a panel of 36 tumor-associated antigens and cellular marker proteins from tumor material of 133 patients with renal cell carcinoma who underwent radical neprhectomy.
Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.
Improvements to progression-free survival (PFS) seen across patient subgroups treated with cabozantinib.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|